Fresenius Medical Care AG (FMS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, Sandra. I would like to welcome everyone to our earnings call for the first quarter 2025. I know that this is a very tough day with many companies in the sector reporting today. Nevertheless, thank you for joining us today. As always, I would like to start out the call by mentioning our cautionary language that is in our safe harbor statement as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. As always, we will have 60 minutes for the call. To give everyone the chance to ask questions, we would like to limit the number of questions to two, like in the past, and it would be great if we could make it work again, as always. Let me now welcome Helen Gieser, CEO and Chair of the Management Board, and Martin Fischer, our Chief Financial Officer. Helen. Thank you, Dominic. I'd like to extend a warm welcome to everyone on the call. Thank you for your continued interest in Fresenius Medical Care. I'm pleased to report that we're off to a great start in 2025. Our first quarter performance further underscores the strength in the execution of our current strategic plan. With the start of the third and final year of our plan, I'm thrilled with our team's energy and focus maintaining momentum, and delivering continued operational and financial progress. I will begin my prepared remarks on slide four. In the first quarter, we delivered strong organic revenue growth of 5%, with positive contributions from both care delivery and care enablement. Despite a severe flu season increasing mistreatments, we realized stable same market treatment growth in the United States. This was possible due to continuously improving unde...